62358 Federal Register / Vol. 65, No. 202 / Wednesday, October 18, 2000 / Notices

applied to acquire 60 percent of the

voting shares of NebraskaLand Financial

Services, Inc., North Platte, Nebraska.

2. First Olathe Bancshares, Inc.,

Kansas City, Missouri; to control

Bannister Bank & Trust Company,

Kansas City, Missouri, through a

management consulting agreement.

Board of Governors of the Federal Reserve

System, October 12, 2000.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 00–26672 Filed 10–17–00; 8:45 am]

BILLING CODE 6210–01–P

GENERAL SERVICES

ADMINISTRATION

Great Lakes Region 5; Intent To

Prepare an Environmental Impact

Statement for the Disposal and

Potential Reuse of Badger Army

Ammunition Plant (BAAP) in Baraboo,

Wisconsin

AGENCY: U.S. General Services

Administration, Great Lakes Region 5.

ACTION: Notice of intent (NOI) to prepare

an Environmental Impact Statement

(EIS), and to conduct public scoping.

SUMMARY: The U.S. General Services

(GSA) is issuing this notice to advise the

public that an Environmental Impact

Statement (EIS) will be prepared to

assess the potential effects of disposal

and potential reuse alternatives of the

Badger Army Ammunition Plant

(BAAP) in Baraboo, Wisconsin. To

ensure that all significant issues related

to the proposed action are identified,

the GSA will conduct a public scoping

meeting.

ADDRESSES: Comments may be mailed

or delivered to the GSA at the following

address: Mr. William Costa, GSA

Property Disposal Division, 10

Causeway Street, Boston, MA 02222–

1077.

FOR FURTHER INFORMATION CONTACT: U.S.

General Services Administration: Mr.

William Costa, (617) 565–5696 or The

Louis Berger Group, Inc.: Mr. Jess

Commerford, (202) 331–7775.

SUPPLEMENTARY INFORMATION: The GSA

will prepare an EIS on disposal of the

Badger Army Ammunition Plant and

potential reuse alternatives. BAAP

covers approximately 7,354 acres in

Sauk County, approximately 6 miles

south of Baraboo and approximately 30

miles northwest of Madison, Wisconsin.

The Sauk County Board of Supervisors

has established the Badger Army

Ammunition Plant Reuse Committee to

develop proposed reuse scenarios for

the property. The EIS will address reuse

issues developed by the Reuse

Committee, which will conclude its

work in March 2001. The environmental

review of the disposal and potential

reuse alternatives will be conducted in

accordance with the requirements of the

National Environmental Policy Act

(NEPA) of 1969, as amended (42 U.S.C.

4371, et seq.), Council on

Environmental Quality (CEQ)

regulations (40 CFR Parts 1500–1508),

U.S. General Services Administration

regulations (PBS P 1095.4 B), and all

applicable Federal, state, and local

government laws, regulations, and

policies.

Public Scoping Meeting

The GSA will solicit public comments

for consideration and possible

incorporation in the Draft EIS through

public scoping, including a scoping

meeting, on the proposed action. To

ensure the full range of issues related to

this proposed action are addressed and

all significant issues are identified early

in the process, comments and

suggestions are invited from all

interested and/or potentially affected

parties. These individuals or groups are

invited to attend the public scoping.

The meeting location and time will be

publicized in local newspapers and

elsewhere. Written comments will be

accepted throughout this process and

can be forwarded to the address

provided above.

Dated: October 11, 2000.

William Costa,

Property Disposal Division, General Services

Administration.

[FR Doc. 00–26746 Filed 10–17–00; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Meeting of the Advisory Committee on

Blood Safety and Availability

AGENCY: Office of the Secretary.

ACTION: Notice of Meeting.

The Advisory Committee on Blood

Safety and Availability will meet on

Thursday, January 25, 2001 and Friday,

January 26, 2001, from 8:00 a.m. to 5:00

p.m.. The meeting will take place at the

Hyatt Regency Hotel on Capitol Hill,

400 New Jersey Ave., NW., Washington,

DC 20001. The meeting will be entirely

open to the public.

The Advisory Committee will

consider how the government should

respond to the current public debate

over universal leukoreduction.

Public comment will be solicited at

the meeting. Public comment will be

limited to five minutes per speaker.

Those who wish to have printed

material distributed to Advisory

Committee members should submit

thirty (30) copies to the Executive

Secretary prior to close of business

January 11, 2001.

FOR FURTHER INFORMATION CONTACT:

Stephen D. Nightingale, M.D., Executive

Secretary, Advisory Committee on

Blood Safety and Availability,

Department of Health and Human

Services, Office of Public Health and

Science, 200 Independence Avenue,

S.W., Rm 736E, Washington, D.C.

20201. Phone (202) 690–5560 FAX (202)

690–7560 e-mail

StephenDNightingale@osophs.dhhs.gov.

Dated: October 6, 2000.

Stephen D. Nightingale,

Executive Secretary, Advisory Committee on

Blood Safety and Availability.

[FR Doc. 00–26739 Filed 10–17–00; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES (HHS)

Administration on Aging

Announcement of Fiscal Year 2000

Sole Source Awards

AGENCY: Administration on Aging, HHS.

ACTION: Announcement of sole source

awards made by the Administration on

Aging in fiscal year (FY) 2000 under the

authority of Title IV of the Older

Americans Act (42 U.S.C. 3001 et seq.).

SUMMARY: The Administration on Aging

announces that it has made twenty-eight

(28) new sole source awards in FY 2000

as follows: National Indian Council on

Aging (NM), $130,000, March 1, 2000 to

February 28, 2003; National Asian

Pacific Center on Aging (WA), $260,000,

March 1, 2000 to February 28, 2003;

Asociacion National Pro Personas

Mayores (CA), $150,000, September 1,

2000 to August 31, 2003; National

Caucus and Center on Black Aged (DC),

$150,000, September 1, 2000 to August

31, 2003; National Hispanic Council on

Aging (DC), $150,000, September 1,

2000 to August 31, 2003; National

Association of Home Builders Research

Center, Inc. (MD), $553,285, April 1,

2000 to March 31, 2001; Christmas in

April USA (DC), $322,756, June 1, 2000

to May 31, 2001; Albert Einstein

Medical Center (PA), $920,000,

September 30, 2000 to February 28,

2002; West Virginia University (WV),

$460,000, May 1, 2000 to April 30, 2001;

Community Programs of Long Island,

Inc. (NY), $461,080, May 1, 2000 to July

31, 2001; Nevada Rural Counties RSVP

Federal Register / Vol. 65, No. 202 / Wednesday, October 18, 2000 / Notices 62359

Program (NV), $92,216, September 1,

2000 to August 31, 2001; University of

Colorado Health Science Center (CO),

$327,364, September 29, 2000 to

September 28, 2003; University of North

Dakota (ND), $327,365, September 1,

2000 to August 31, 2003; Metropolitan

Family Services (IL), $250,000,

September 30, 2000 to September 29,

2001; Santa Clara Indian Pueblo (NM),

$461,000, September 1, 2000 to August

31, 2001; City of Norwalk (CA), $36,886,

September 30, 2000 to September 29,

2001; Elderly Services Inc. (VT),

$783,836, September 30, 2000 to March

30, 2002; VNA Home Health, Inc. (WI),

$89,575, September 1, 2000 to August

31, 2001; City of Norwalk (CA), $36,886,

September 30, 2000 to September 29,

2001; Pension Rights Center (DC),

$187,500, April 1, 2000 to March 30,

2003; Legal Services for the Elderly

(NY), $75,000, March 1, 2000 to

February 28, 2003; California Advocates

for Nursing Home Reform (CA), $75,000,

March 1, 2000 to February 28, 2003;

Older Womens League, Inc. (DC),

$74,919, May 1, 2000 to April 30, 2003;

Pima Council on Aging (AZ), $75,000,

May 1, 2000 to April 30, 2003; Chicago

Department on Aging (IL), $74,353,

September 30, 2000 to September 29,

2003; University of Alabama (AL),

$74,928, September 30, 2000 to

September 29, 2003; Oregon Health

Sciences University (OR), $922,160,

August 1, 2000 to January 31, 2002; and

Texas Tech University Health Sciences

Center School of Medicine (TX),

$1,857,786, August 1, 2000 to July 31,

2001.

All awards were made consistent with

the terms of Senate Report 106–166 and

House Report 106–370 which

accompany the Consolidated

Appropriations Act for FY 2000 (Pub. L.

106–113).

FOR FURTHER INFORMATION CONTACT:

Edwin L. Walker, 202–619–1828.

Dated: October 10, 2000.

Jeanette C. Takamura,

Assistant Secretary for Aging.

[FR Doc. 00–26734 Filed 10–17–00; 8:45 am]

BILLING CODE 4154–01–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96M–0311]

Agency Information Collection

Activities; Submission for OMB

Review; Comment Request; Public

Health Service (PHS) Guideline on

Infectious Disease Issues in

Xenotransplantation

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that the proposed collection of

information listed below has been

submitted to the Office of Management

and Budget (OMB) for review and

clearance under the Paperwork

Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the

collection of information by November

17, 2000.

ADDRESSES: Submit written comments

on the collection of information to the

Office of Information and Regulatory

Affairs, OMB, New Executive Office

Bldg., 725 17th St. NW., rm. 10235,

Washington, DC 20503, Attn: Wendy

Taylor, Desk Officer for FDA.

FOR FURTHER INFORMATION CONTACT:

JonnaLynn P. Capezzuto, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In

compliance with 44 U.S.C. 3507, FDA

has submitted the following proposed

collection of information to OMB for

review and clearance.

PHS Guideline on Infectious Disease

Issues in Xenotransplantation

The statutory authority to collect this

information is provided under sections

351 and 361 of the PHS Act (42 U.S.C.

262 and 264) and the provisions of the

Federal Food, Drug, and Cosmetic Act

that apply to drugs (21 U.S.C. 301 et

seq.). This PHS guideline is revised

based on public comment to a previous

document entitled ‘‘Draft Public Health

Service (PHS) Guideline on Infectious

Disease Issues in Xenotransplantation

(August 1996),’’ which published in the

Federal Register of September 23, 1996

(61 FR 49919). The PHS guideline

recommends procedures to diminish the

risk of transmission of infectious agents

to the xenotransplantation product

recipient and the general public. The

PHS guideline is intended to address

public health issues raised by

xenotransplantation, through

identification of general principles of

prevention and control of infectious

diseases associated with

xenotransplantation that may pose a

hazard to the public health. The

collection of information described in

this guideline is intended to provide

general guidance to sponsors in: (1) The

development of xenotransplantation

clinical protocols, (2) the preparation of

submissions to FDA, and (3) the

conduct of xenotransplantation clinical

trials. Also, the collection of

information will help ensure that the

sponsor maintains important

information in a cross-referenced system

that links the relevant records of the

xenotransplantation product recipient,

xenotransplantation product, source

animal(s), animal procurement center,

and significant nosocomial exposures.

The PHS guideline describes an

occupational health service program for

the protection of health care workers

involved in xenotransplantation

procedures, caring for

xenotransplantation product recipients,

and performing associated laboratory

testing. The PHS guideline also

describes public health needs for: (1) A

pilot national xenotransplant data base,

which is currently under development

by PHS; (2) a central PHS biologic

specimen archive; and (3) the

Secretary’s Advisory Committee on

Xenotransplantation, which is being

developed and implemented by the

Department of Health and Human

Services. These public health programs

and this PHS guideline are intended to

protect the public health and help

ensure the safety of using

xenotransplantation products in

humans by preventing the introduction,

transmission, and spread of infectious

diseases associated with

xenotransplantation.

Respondents to this collection of

information are the sponsors of clinical

studies of investigational

xenotransplantation products under

investigational new drug applications

(IND’s) and xenotransplantation product

procurement centers, referred to as

source animal facilities. Currently, there

are 11 respondents who are sponsors of

IND’s, which include protocols for

xenotransplantation in humans. Other

respondents for this collection of

information are 18 source animal

facilities which provide source

xenotransplantation product material to

sponsors for use in human

xenotransplantation procedures. These

18 source animal facilities keep medical

records of the herds/colonies as well as